Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372881 | 1.00 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL372987 | 1.00 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| Hydrochloric Acid SCHEMBL373321 | 0.99 | LMNA (0.55) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL7043759 | 0.92 | CHRNA7 (0.53) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL701090 | 0.86 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL7043317 | 0.84 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4LMNAALDH1A1 | |
| SCHEMBL6152811 | 0.84 | SMN1; SMN2 (0.70) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL6152809 | 0.84 | SMN1; SMN2 (0.70) | CHRNA7CHRNB2CHRNA4LMNACTSK | |
| SCHEMBL700513 | 0.83 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7042267 | 0.83 | TDP1 (0.44) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270203-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2025-08-28 | — | — | US | disclosed |
| CN-119212992-A | Nicotinic acetylcholine receptor ligands | 菲利普莫里斯生产公司 | 2024-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270203-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA1, CHRNA6 | CHRNA7 1/4885CHRNB2 16/4885CHRNA4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.